8-K: Outlook Therapeutics Submits UK Application for Wet AMD Treatment Following Positive EU Opinion

Outlook Therapeutics has submitted a Marketing Authorization Application to the UK's MHRA for its ONS-5010/LYTENAVA treatment for wet age-related macular degeneration, following a positive opinion from the EU's CHMP.

Summary

• Outlook Therapeutics has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration (wet AMD).
• The submission leverages the International Recognition Procedure (IRP), allowing the MHRA to consider the positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
• The CHMP had previously issued a positive opinion on March 22, 2024, regarding the authorization of ONS-5010/LYTENAVA in the EU.
• The European Commission is expected to make a decision within approximately 67 days of the CHMP opinion, which will automatically apply to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein within 30 days.
• ONS-5010/LYTENAVA is an investigational ophthalmic formulation of bevacizumab, intended for intravitreal injection to treat wet AMD and other retinal diseases.
• Currently, no FDA or European Commission approved ophthalmic formulations of bevacizumab are available, leading clinicians to use repackaged IV bevacizumab with associated risks.
• If approved, ONS-5010/LYTENAVA would be the first authorized ophthalmic bevacizumab for treating wet AMD in the US, EU, and UK.
• The MAA submission is supported by results from three completed clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.
• Outlook Therapeutics has a strategic commercialization agreement with Cencora for logistics, distribution, and pharmacovigilance services in the US, EU, and UK.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the progress in regulatory submissions and the potential for a first-in-class product. The use of the IRP and the positive CHMP opinion are strong indicators of potential success. However, the inherent risks in drug development and regulatory approvals temper the overall sentiment.

Positives

• The submission of the MAA to the MHRA is a significant step towards potential authorization of ONS-5010/LYTENAVA in the UK.
• The use of the International Recognition Procedure (IRP) streamlines the approval process in the UK.
• The positive opinion from the CHMP in the EU provides strong support for the UK application.
• If approved, ONS-5010/LYTENAVA would be the first authorized ophthalmic bevacizumab for treating wet AMD, offering a safer alternative to repackaged IV bevacizumab.
• The strategic commercialization agreement with Cencora will facilitate the distribution and market reach of the product.

Negatives

• The document does not explicitly mention any negatives, but it does highlight the risks associated with developing pharmaceutical product candidates, conducting clinical trials, and obtaining regulatory approvals.

Risks

• The company faces risks associated with developing pharmaceutical product candidates.
• There are risks involved in conducting clinical trials and obtaining necessary regulatory approvals.
• The content and timing of decisions by the FDA and other regulatory bodies are uncertain.
• Market conditions and macroeconomic factors, including overseas conflicts, high interest rates, inflation, and potential bank failures, could impact the business.
• There is no guarantee that the European Commission or MHRA will approve the application.

Future Outlook

Outlook Therapeutics anticipates potential authorization of ONS-5010/LYTENAVA in the UK and EU, and expects to commercialize it as the first approved ophthalmic formulation of bevacizumab for retinal diseases in the US, EU, and UK. They also plan to seek authorization in other European markets and Japan.

Management Comments

• Russell Trenary, President and CEO of Outlook Therapeutics, stated that the MAA submission to the MHRA is another step closer to offering clinicians and patients in the UK the only on-label, ophthalmic bevacizumab to treat wet AMD.
• Russell Trenary also noted that they continue to make noteworthy progress toward the potential authorization of ONS-5010/LYTENAVA in the UK following the recent positive opinion by the CHMP in the EU.

Industry Context

This announcement is significant as it addresses the unmet need for an approved ophthalmic formulation of bevacizumab for treating retinal diseases. Currently, clinicians use repackaged IV bevacizumab, which carries risks of contamination and inconsistent potency. The approval of ONS-5010/LYTENAVA would provide a safer and more reliable option, potentially disrupting the market for off-label bevacizumab use.

Comparison to Industry Standards

• Currently, there are no approved ophthalmic formulations of bevacizumab for wet AMD, making ONS-5010/LYTENAVA a potential first-in-class product.
• Competitors in the wet AMD market include companies offering other anti-VEGF treatments such as ranibizumab (Lucentis) and aflibercept (Eylea), which are approved for ophthalmic use.
• The use of repackaged IV bevacizumab is a common off-label practice, but it lacks the safety and consistency of a purpose-built ophthalmic formulation.
• The IRP process used for the UK submission is designed to expedite approvals for products already reviewed by a Reference Regulator, such as the EMA, which is a common practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may see a positive impact from the progress in regulatory approvals and potential market launch.
• Clinicians would have access to a safer and more reliable treatment option for wet AMD.
• Patients with wet AMD could benefit from an approved ophthalmic formulation of bevacizumab.
• Cencora will benefit from the commercialization agreement with Outlook Therapeutics.

Next Steps

• The European Commission is expected to make a decision on the EU application within approximately 67 days of the CHMP opinion.
• The MHRA will review the MAA submission for ONS-5010/LYTENAVA in the UK.
• Outlook Therapeutics will continue to work towards regulatory approvals in other markets, including the US, EU, and Japan.

Key Dates

Keywords

ONS-5010, LYTENAVA, bevacizumab, wet AMD, retinal diseases, MHRA, CHMP, MAA, Marketing Authorization Application, ophthalmic, biopharmaceutical, regulatory approval